Best practices as recommended by WHO and United States Pharmacopoeia are being implemented for performing tests on therapeutic goods.
Recent Updates
- Recall Alert: Drug Products; Recall of 11 Substandard Batches from the Market September 6, 2024
- Minutes of 339th meeting of Registration Board held on 6th – 8th August, 2024 September 3, 2024
- S.R.O. 1324(l)12024 – Revision of Regulatory Fee Notification September 2, 2024
- Orientation Session For Pharmaceutical Manufacturers on PIC/s GMP Guidelines August 23, 2024
- Rapid Alert: Falsified Propylene Glycol in Supply Chain Market August 22, 2024
- DRAP Switched Over to Pakistan Single Window (PSW) for Regulatory Controls on Crossborder Trade at Karachi Custom Stations August 20, 2024
- Stakeholders Comments are invited on Draft Guidelines On Submission of Expenditure Details Under the Ethical Marketing To Healthcare Professionals Rules, 2021 August 9, 2024
- Revocation of Form-6 (provisional certificate for enlistment as manufacturer /importer & Form-7 (provisional certificate for enlistment of products) August 8, 2024
- DRAP Pharmacovigilance Newsletter-August 2024 July 31, 2024
- Registration Board directed manufacturers to follow USP Monograph for Ciprofloxacin Oral Suspension July 25, 2024
Leadership
- Nadeem Mahbub
Secretary, Ministry of NHSR&C - Mr. Asim Rauf
Chief Executive Officer, DRAP
Announcement
We are pleased to announce that the Drug Regulatory Authority of Pakistan (DRAP) has shifted its head office from G-9/4, Islamabad to the new location in Prime Minster's National Health Complex, Islamabad. All new correspondence should be addressed to our new head office location. Please update your records accordingly. Additionally, we are currently in the process of transferring and we are committed to ensure smooth transition to avoid any inconvenience during this time. Thank you for understanding and cooperation.
![E-Services](https://i0.wp.com/www.dra.gov.pk/wp-content/uploads/2021/05/clean-code.jpg?resize=600%2C330&ssl=1)
E-Services
With the effective use of Information Technology, we have implemented a number of online services and continually working for more. Click Here to Register an account for following online services. Online Challan & Fee Submission fee.dra.gov.pk Commercial Import & Export
![Guidelines](https://i0.wp.com/www.dra.gov.pk/wp-content/uploads/2022/01/atlas-1052011_960_720.jpg?resize=600%2C330&ssl=1)
Guidelines
Regulatory compliance is essential and indispensable in order to assure the safety, quality and efficacy of therapeutic goods. Guidance documents published by the Authority are meant to explain the current interpretation or policy for better understanding of the industry and
![Quality Control Labs](https://i0.wp.com/www.dra.gov.pk/wp-content/uploads/2021/12/laboratory-5721287_960_720.webp?resize=600%2C330&ssl=1)
Quality Control Labs
For ensuring quality therapeutic goods, a network of quality control laboratories has been established. DRAP approved products and suspect therapeutic goods are tested for their quality in accordance with best international practices. To keep the citizens safe from substandard and
![Therapeutic Products Recalls](https://i0.wp.com/www.dra.gov.pk/wp-content/uploads/2022/11/recalls.png?resize=474%2C260&ssl=1)
Therapeutic Products Recalls
The Recalled Product Index provides access to consumers, healthcare professionals, industry, hospitals and sale outlets related to the information of recalled action taken for defective therapeutic goods. The following section provides an index of recalled actions in which a public
![Health Professional Alerts](https://i0.wp.com/www.dra.gov.pk/wp-content/uploads/2022/06/stethoscope-6497490_960_720.webp?resize=600%2C330&ssl=1)
Health Professional Alerts
DRAP’s issues safety updates and alerts related to the therapeutic goods in order to ensure that healthcare professionals and other stakeholders have timely access to the relevant information on safety, quality and efficacy issues or benefit/risk evaluations of the drugs,
![Open Consultations](https://i0.wp.com/www.dra.gov.pk/wp-content/uploads/2022/06/cms-265128_960_720.jpg?resize=600%2C330&ssl=1)
Open Consultations
Public consultation enables organizations to consider views and ideas from the citizens and relevant stakeholders during the development of new regulatory mechanisms, either through the enactment of new rules and policies or changes to existing ones or by the development
eApp and centralized Case Management System
We are delighted to announce that DRAP has enabled eApp for Drug Licensing & Registration application submissions. Moreover, we have introduced centralized Case Management System in the same portal for enhanced efficiency and transparency.
Do you know?
DRAP ensures that every drug, medical device or cosmetic, alternative medicine and health product must have a certain standard of quality and is safe and effective for your use. See in links below how it is done and what to do in case you find a suspect therapeutic good.